| Name | Title | Contact Details |
|---|
CUBE is the worlds most comprehensive and robust source of classified, and meaningful AI-driven regulatory intelligence. CUBEs purpose-built regulatory AI engine (RegAI) and tech platform (RegPlatform) tracks, analyses, and monitors laws, rules, and regulations in every country and in every published language to create an always up-to-date regulatory footprint, mapping these according to data, transforming visibility and compliance capability. With operations across Europe, North America, Asia, and Australia, CUBE serves a diverse and global base of customers and partners including the largest financial institutions in the world who leverage CUBEs RegPlatform to streamline their complex regulatory change management and compliance processes. Whether youre a large, multinational bank, or a small financial organisation with up to a handful of compliance officers, we have a suite of products tailored to you.
The Herlitz Company is a Larchmont, NY-based company in the Business Services sector.
Leisures Lanes is a Monroe, WI-based company in the Business Services sector.
Alico Inc is a Labelle, FL-based company in the Business Services sector.
Oculis (Nasdaq: OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.